glp 1 medication retatrutide What GLP‑3 Really Is: Triple‑Receptor Drug Semaglutide vs. Tirzepatide vs. Retatrutide

Centralized approvals speed multinational launches, but national cost-effectiveness reviews temper revenue per patient

Healthcare providers assess each patient individually to determine whether the benefits outweigh potential risks

Finally, although most of the evidence of a potential benefit of GLP-1 RAs in HF originates from CVOTs in type 2 diabetes, it may likely be in the weight management setting that the drug class could be of the highest clinical value, particularly in people with HFpEF

J Clin Med 12(18):5921 Chao AM, Tronieri JS, Amaro A et al (2023) Semaglutide for the treatment of obesity

Zhang J, Han X, Li X, Luo Y, Zhao H, Yang M, et al